Menu
← Oncology Approval Tracker
FDA DECISION ·
Adcetris
brentuximab vedotin · Seagen (Pfizer)
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
With lenalidomide and a rituximab product for adults with relapsed or refractory large B-cell lymphoma after two or more systemic lines who cannot undergo autologous transplant or CAR T-cell therapy; eligible histologies include DLBCL not otherwise specified, DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma.
LAMPGEN ANALYSIS
Why it matters
The combination provides a CD30-directed antibody–drug conjugate regimen for heavily pretreated patients who cannot proceed to cellular therapy.
What research teams should watch
Capture the reason for transplant or CAR T ineligibility and coordinate oral lenalidomide dispensing with infusion visits.
PRIMARY RECORDS